# US 2016/0235870 A1 · Multifunctional chelators, complexes, and compositions thereof, and methods of using same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0235870 A1
- Document ID: US20160235870A1
- Status: Published application
- Kind: A1
- Application number: 15/027,104
- Filed: 2014-10-06
- Published: 2016-08-18
- Earliest claimed: 2013-10-04
- Assignees: Illinois Institute of Technology
- Applicants: Illinois Institute of Technology
- Inventors: Hyun-Soon CHONG
- Web page: https://patentgrep.com/patent/US20160235870A1

## CPC

- A61K 51/0482: {chelates from cyclic ligands, e.g. DOTA}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 255/02: not condensed with other rings
- C07D 257/02: not condensed with other rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- A61K 51/0474: {complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Multifunctional chelators, metal complexes thereof, compositions thereof, and methods of making and use in diagnostic imaging and treatment of cellular disorders.

## Claims

### Claim 1

A compound of formula (I):
where k is 0 or 1; m is 0 or 1; and each of Y1-Y4 independently is one of a structure of formula (a-1), (a-2), or (a-3):
where p is 1 or 2; Z is hydrogen, formula (a-2), formula (a-3), Ar, a pyridylalkyl, a protecting group, an aryl containing group, an alkynyl containing group, an amine containing group, an azide containing group, or an amide containing group; Ar is or includes an aromatic ring or a heteroaromatic ring; and each R′ independently is OH, NH2, OR″, NR2″ wherein each R″ is one of alkyl, tert-butyl, allyl, benzyl, or a protecting group; and
wherein each of R1-18 independently is or includes hydrogen, carboxyalkyl, alkylamido, alkyl, allyl, benzyl, benzyloxyalkyl, cycloalkyl, alkoxy, hydroxyalkyl, aryl, aryloxy, hydroxyaryl, heteroaryl, phenyl, vinyl, alkynyl, alkenyl, furannylalkyl, alkylthioalkyl, arylhydroxyalkyl, indanyl, inolylalkyl, naphthylalkyl, imidazolylalkyl, pyridiylalkyl, benzothiophenylalkyl, thiophenylalkyl, thioalkyl, thioaryl, thiobenzyl, hydroxy, an alkynyl containing group, substituted carbonyl, hydroxyalkyl, triazolylalkyl, aminoalkyl, benzothiophenylalkyl, carboxyl, carboxyalkyloxy, amine, a protected amine, carboxylic acid, holoalkylamido, aldehyde, ester, amido, tosyl, phthalimidyl, maleimidyl, trityl, tert-butyloxycarbonyl, carbobenzyloxy, o-nosyl, acetyl, fluoroacetyl, dimethoxybenzyl, p-methoxybenzyl, an amide containing group, a thioamide containing group, an amino acid-containing group, an ester containing group, a protecting group, an amine protecting group or:
where W is NH, oxygen, or sulfur, n is 1-5, and each of X1-X5 independently is or includes hydrogen, halo, cyano, alkyl, hydroxy, nitro, amino, alkylamino, thiocyano, isothiocyano, alkoxy, aryloxy, carboxyl, carboxyalkyl, carboxyalkyloxy, ester, amido, aldehydo, alkylamido, holoalkylamido, an ester containing group, an carbonyl containing group, an amide containing group, an amine containing group, a thioamide containing group, an alkynyl containing group, or an amino acid-containing group.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the compound is formula (II):
where k is 0 or 1; m is 0 or 1; each of V1-V2 independently is one of the following:
and each of Y1-Y2 independently is one of the following:
wherein R19-20 is defined as for R1-18.

### Claim 3 (depends on 1)

The compound of claim 1, wherein more than one of Y1-Y4 is formula (a-1).

### Claim 4 (depends on 1)

The compound of ene of the claim 1, wherein at least one Z of Y1-Y4 is hydrogen.

### Claim 5 (depends on 1)

The compound of claim 1, wherein Ar is selected from:
where W is NH, oxygen, or sulfur, n is 1-5, and each of X1-X5 independently is or includes hydrogen, halo, cyano, alkyl, hydroxy, nitro, amino, alkylamino, thiocyano, isothiocyano, alkoxy, aryloxy, carboxyl, carboxyalkyl, carboxyalkyloxy, ester, amido, aldehydo, alkylamido, holoalkylamido, an ester containing group, an carbonyl containing group, an amide containing group, an amine containing group, a thioamide containing group, an alkynyl containing group, or an amino acid-containing group.

### Claim 6 (depends on 1)

The compound of claim 1, wherein one of R13-R18 comprises:
where n is 1-5.

### Claim 7 (depends on 1)

The compound of claim 1, wherein X5 comprises NO2.

### Claim 8 (depends on 1)

The compound of claim 1, wherein at least three of Y1-Y4 is formula (a-1).

### Claim 9 (depends on 1)

The compound of claim 1, wherein at least one of Y1-Y4 is selected from:
where W is NH, oxygen, or sulfur and n is 1-5.

### Claim 10 (depends on 9)

The compound of claim 9, wherein at least one of Y1-Y4 comprises:
where X1 is described above or comprises NH2, NHBoc, NCS or NHPhth.

### Claim 11 (depends on 9)

The compound of claim 9, wherein an other of Y1-Y4 is formula (a-3) with one of R17-18 comprising:
and n is 1-5.

### Claim 12 (depends on 1)

The compound of claim 1, wherein at least one of Y1-Y4 is formula (a-1), and Z is selected from:
where W is NH, oxygen, or sulfur and n is 1-5.

### Claim 13 (depends on 12)

The compound of claim 12, wherein an other of Y1-Y4 is formula (a-3) with one of R17-18 comprising:
and n is 1-5.

### Claim 14 (depends on 12)

The compound of claim 12, wherein Z comprises:
where X1 is described above or comprises NH2, NHBoc, NCS or NHPhth.

### Claim 15 (depends on 1)

The compound of claim 1, wherein k is 1.

### Claim 16 (depends on 1)

A complex comprising the compound of claim 1 and a metal ion, a radioactive isotope of the metal ion, or a radioactive isotope of carbon, nitrogen, iodine, fluorine, oxygen, or helium.

### Claim 17 (depends on 16)

The complex of claim 16, wherein the metal ion is selected from the group consisting of Ac, Al, Bi, Pb, Y, Mn, Cr, Fe, Co, Zn, Ni, Tc, Gd, In, Ga, Cu, Re, Sm, Pm, Ho, Zr, Am, Ce, U, a lanthanide, and an actinide.

### Claim 18 (depends on 1)

A conjugate comprising the compound of claim 1 and a targeting moiety, a fluorescence moiety, or a nanoparticle.

### Claim 19 (depends on 18)

The conjugate according to claim 18, wherein the targeting moiety comprises a biomolecule selected from a hormone, a bile acid, an amino acid, a peptide, a peptidomimetic, a protein, a deoxyribonucleic acid (DNA), a ribonucleic acid (RNA), a lipid, an albumin, a receptor molecule, a receptor binding molecule, a hapten, a monoclonal antibody, a polyclonal antibody, a peptide, an aptamer, a folic acid, an estrogen, or a transferrin.

### Claim 20 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 1)

A method of generating a diagnostic image or measurement, the method comprising:
administering to an animal a composition comprising the compound of claim 1; and
imaging or measuring an amount of the composition in a tissue or organ of the animal using magnetic resonance imaging (MRI), fluorescence imaging (FI), x-ray contrast imaging, transmission electron microscopy imaging, a positron emission tomography (PET) imaging, or single photon emission computed spectroscopy (SPECT).

### Claim 22 (depends on 1)

A method of treating cancer, iron overload disease, or neurodegenerative or infectious diseases including Alzheuner's disease (AD), Parkinson's disease (PD), tuberculosis, HIV, fungal disease, or amalaria disease in a mammal, comprising the step of administering to the mammal a composition comprising a compound of claim 1 in an amount effective to treat the cancer, the iron overload disease, the neutrodegenerative or infectious diseases, wherein the cancer is selected from the group consisting of lymphomas, leukemias, hepatic, colo-rectal cancer, ovarian cancer, breast cancer, and prostate cancer.

### Claim 23 (depends on 20)

The method of claim 20, wherein the complex comprises 90Y, 86Y, 111In, 213Bi, 212Bi, 212Pb, 225Ac, 177Lu, 68Ga, 166Ho, 153Sm, 149Pm, 64Cu, 89Zr, 18F or 67Cu.

### Claim 24 (depends on 1)

A method of preparing the compound of claim 1, comprising:
reacting a compound of formula (Ib-1):
wherein: m is 0 or 1; each of R1-12 and Y1-3 is as defined above, with a compound of formula (Ib-2) or (Ib-3):
where m is 0 or 1; p is 0 or 1; each of R21-22 independently is as defined for R1-20; and Q is a counter anion or a leaving group comprising halide, perchlorate, tetrafluoroborate, hexafluoroantimonate, mesylate, triflate, tosylate, carbonate, nitrate, phthalimide, or succinimide.

### Claim 25 (depends on 24)

The method of claim 24, further comprising providing a compound of formula (f-1):

### Claim 26 (depends on 25)

The method of claim 25, further comprising: converting (b-2) to (b-3) in the presence of halosequestering agent comprising AgClO4, AgOTf, Ag2CO3, AgOTs, AgNO3, AgSbF6, or AgBF4; and reacting (b-3) in situ with (Ib-1) to obtain (f-1).
